Clinical trials: Renal Insufficiency
End Stage Renal Disease, Renal Impairment
A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 120 mg dose in participants with end stage renal disease (ESRD) before and after hemodialysis (HD)…
- Trial name
- NCT04994522
- Testing
- Belzutifan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Type 2 Diabetes
A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
A Phase 2 study of RTA 402 in Chronic kidney disease (CKD) patients with type 2 diabetes mellitus.
- Trial name
- NCT01574365
- Testing
- RTA 402
- Where
- Japan
- Volunteers
- 53 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
This study was conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood.
- Trial name
- ALPS (NCT01887600)
- Testing
- Roxadustat
- Where
- 138 sites in Belarus, Belgium and 20 more
- Volunteers
- 594 people
- Sponsor
- Astellas Pharma Europe B.V.
Anemia
Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis
The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in Chinese patients receiving peritoneal dialysis with chronic kidney disease and anemia
- Trial name
- NCT06720233
- Testing
- SAL-0951 tablets
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Subjects With Varying Degrees of Renal Insufficiency and, Subjects With Normal Renal Function
The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency
RPX7009(beta-lactamase inhibitor) is being studied in combination with carbapenem (RPX2014)to treat bacterial infections, including those due to multi-drug resistant bacteria.
- Trial name
- NCT02020434
- Testing
- RPX7009 and RPX2014
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
End Stage Renal Disease
A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis
Objective: The purpose of this study is to demonstrate: -the non-inferiority of an experimental peritoneal dialysis solution compared to a current solution for the management of end stage renal disease (ESRD) in peritoneal…
- Trial name
- NCT00214721
- Testing
- Experimental Peritoneal Dialysis Solution
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Vantive Health LLC
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Approximately 56 participants who are 1 month old to 17 years old will be enrolled in this study. The total duration for this study will be 38 weeks (or up to 42 weeks when participants require a washout period due to prior…
- Trial name
- NCT07890584
- Testing
- PLS240, Standard of Care
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Pathalys Pharma
Gastrointestinal Cancer
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
This trial is a phase II study in patients with advanced gastrointestinal (GI) malignancies who will be assigned to one of 4 cohorts (normal, mild, moderate and several renal dysfunction) based on their baseline measured…
- Trial name
- FOLFOX4 (NCT00094965)
- Testing
- Oxaliplatin (SR96669)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Sanofi
Chronic Kidney Disease
SGLT2 Inhibitors and Renal Anemia in Japan: RWD
The objectives of the study are: 1. To evaluate the association between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor use and the occurrence of anemia in patients with chronic kidney disease (CKD) using a nested case-control…
- Trial name
- NCT07063316
- Testing
- SGLT2 inhibitor
- Where
- Japan
- Volunteers
- 15,000 people
- Sponsor
- Boehringer Ingelheim
Hyperphosphatemia, Chronic Kidney Disease
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
To evaluate the superiority to placebo, dose-responsibility and safety.
- Trial name
- NCT00505037
- Testing
- ASP1585, Sevelamer hydrochloride
- Where
- 6 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Astellas Pharma Inc
End Stage Renal Disease, Inflammation
Evaluation of Biocompatibility and Performances of 4 Dialyzers in Different Mode Treatments
Prospective multicenter randomized cross-over study Number of patients : 32 (8 patients per group) Obtain objectives data to advise each hemodialyzer according to dialysis treatment and patient profile.
- Trial name
- BIOMODAL (NCT03262272)
- Testing
- VIE A Hemodialyzer, Rexsys 27H hemodialyzer, Leoceed 21HX hemodialyzer
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Hemotech
Chronic Renal Failure
Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
Renamezin Capsule (an oral adsorbent) lowers indoxyl sulfate levels in patient with chronic renal failure. 120 patients with chronic renal failure(baseline serum creatinine:1.5-5.0mg/dl). Renamezin is administered 6.0mg/day.
- Trial name
- NCT02681991
- Testing
- Renamezin capsule
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403
This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are planned (5 groups of 6 subjects each.)
- Trial name
- NCT01131091
- Testing
- SK-0403
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Obesity &Amp; Overweight, Chronic Kidney Disease
UBT251 Injection Phase II Clinical Study (CKD)
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
- Trial name
- NCT07134335
- Testing
- UBT251
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
End Stage Renal Disease
Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China
This is a multicenter, randomized, open-label study to compare QoL in subjects with end-stage renal disease (ESRD) requiring PD or conventional in-center HD treatment.
- Trial name
- NCT02378350
- Testing
- Hemodialysis treatment (no specific device is defined), Peritoneal Dialysis treatment (no specific drug is defined)
- Where
- 21 sites in China
- Volunteers
- 668 people
- Sponsor
- Vantive Health LLC
Acute Kidney Injury
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo.
- Trial name
- KOURAGE (NCT06374797)
- Testing
- Auxora
- Where
- 33 sites in United States
- Volunteers
- 122 people
- Sponsor
- CalciMedica, Inc.
Kidney Failure, Chronic
A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis
The purpose of this study is to look at the tolerability and safety of LY3113593. Study doctors will see how safe it is and whether it produces side effects following a single injection into a vein or under the skin in healthy…
- Trial name
- NCT02144285
- Testing
- LY3113593
- Where
- 3 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Acute Kidney Injury
VIDAS Nephroclear (NCL) CCL14 - Sample Stability
This VIDAS® NEPHROCLEAR™ CCL14 (VIDAS® NCL™ CCL14) Sample Stability clinical trial is a multicenter, prospective, and qualitative study.
- Trial name
- NCT05271617
- Testing
- VIDAS® NEPHROCLEAR™ CCL14
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- BioMérieux
Anaemia
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.
- Trial name
- NCT03029208
- Testing
- Daprodustat, Darbepoetin alfa, Iron therapy
- Where
- 111 sites in United States, Argentina and 13 more
- Volunteers
- 312 people
- Sponsor
- GlaxoSmithKline
Renal Impairment, Renal Insufficiency
Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients
This study is being conducted in order to assess the need for dose adjustment for elafibranor in participants with renal impairment.
- Conditions
- Renal Impairment, Renal Insufficiency, Kidney Diseases, Pharmacokinetics
- Trial name
- NCT03844555
- Testing
- Elafibranor
- Where
- 2 sites in France, Romania
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Genfit
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.